Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Leucine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.69 |
| ▸ | SLC1A3 | P43003 | 6/20 | 0.55 |
| ▸ | SLC1A2 | P43004 | 6/20 | 0.55 |
| ▸ | SLC1A1 | P43005 | 6/20 | 0.48 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.41 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.41 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.41 |
| ▸ | GRIK1 | P39086 | 4/20 | 0.40 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.40 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.39 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.39 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.39 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.38 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.38 |
| ▸ | GRIK3 | Q13003 | 2/20 | 0.38 |
| ▸ | GRIK5 | Q16478 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Leucine SCHEMBL27569034 | 1.00 | SLC7A5 (0.69) | SLC7A5SLC1A3SLC1A2SLC1A1CACNA2D1 | |
| Leucine SCHEMBL6129074 | 0.96 | SLC7A5 (0.64) | SLC7A5SLC1A3SLC1A2SLC1A1CACNA2D1 | |
| Leucine SCHEMBL5520318 | 0.92 | SLC7A5 (0.82) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| D-Leucine SCHEMBL1537345 | 0.92 | SLC7A5 (0.82) | SLC7A5SLC1A3SLC1A2SLC1A1CACNA2D1 | |
| D-Leucine SCHEMBL18114536 | 0.92 | SLC7A5 (0.82) | SLC7A5SLC1A3SLC1A2SLC1A1CACNA2D1 | |
| Leucine SCHEMBL4011464 | 0.92 | SLC7A5 (0.82) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| Leucine SCHEMBL5520323 | 0.92 | SLC7A5 (0.82) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| Leucine SCHEMBL625031 | 0.92 | SLC7A5 (0.82) | SLC7A5SLC1A3SLC1A2SLC1A1CACNA2D1 | |
| Leucine SCHEMBL2154089 | 0.92 | SLC7A5 (0.82) | SLC7A5SLC1A3SLC1A2SLC1A1CACNA2D1 | |
| Leucine SCHEMBL4639771 | 0.92 | SLC7A5 (0.82) | SLC7A5SLC1A3SLC1A2SLC1A1CACNA2D1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1601330-A4 | ANTITUMOR AGENTS COMPRISING A TARGETING PORTION AND AN IMMUNE RESPONSE TRIGGERING PORTION | GHC RES DEV CORP (US) | 2008-05-07 | — | — | EP | claimed |
| CN-1787838-A | Antitumor agent comprising targeting moiety and immune response triggering moiety | GREENVILLE HOSPITAL SYSTEM (US) | 2006-06-14 | — | — | CN | claimed |
| EP-1601330-A2 | ANTITUMOR AGENTS COMPRISING A TARGETING PORTION AND AN IMMUNE RESPONSE TRIGGERING PORTION | Greenville Hospital System (US) | 2005-12-07 | — | — | EP | claimed |
| US-20050164182-A1 | Nucleoside comprising reporter molecule cleavable by hydrolase such as esterases, phosphatases, peptidases, penicillin amidases, glycosidases, and phosphorylases; limits polymerase activity; sequencing; solid phase synthesis | GE HEALTHCARE UK LIMITED (GB) | 2005-07-28 | — | — | US | claimed |
| JP-2005517646-A | — | — | 2005-06-16 | — | — | JP | claimed |
| US-20050025771-A1 | Antitumor agents comprising a targeting portion and an immune response triggering portion | GREENVILLE HOSPITAL SYSTEM | 2005-02-03 | — | — | US | claimed |
| WO-2004078137-A2 | ANTITUMOR AGENTS COMPRISING A TARGETING PORTION AND AN IMMUNE RESPONSE TRIGGERING PORTION | GREENVILLE HOSPITAL SYSTEM (US) | 2004-09-16 | — | — | WO | claimed |
| EP-1451201-A2 | NUCLEOTIDE ANALOGUES AND THEIR USE FOR NUCLEIC ACID SEQUENCING | Amersham Biosciences UK Limited (GB) | 2004-09-01 | — | — | EP | claimed |
| WO-2003048178-A2 | NUCLEOTIDE ANALOGUES AND THEIR USE FOR NUCLEIC ACID SEQUENCING | AMERSHAM BIOSCIENCES UK LIMITED (GB) | 2003-06-12 | — | — | WO | claimed |
| US-20240124892-A1 | ADENO-ASSOCIATED VIRUSES AND METHODS AND MATERIALS FOR MAKING AND USING ADENO-ASSOCIATED VIRUSES | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2024-04-18 | — | — | US | disclosed |
| US-20230165952-A1 | BETACORONAVIRUS PROPHYLAXIS AND THERAPY | Nykode Therapeutics ASA (NO) | 2023-06-01 | — | — | US | disclosed |
| EP-4143210-A1 | BETACORONAVIRUS PROPHYLAXIS AND THERAPY | Nykode Therapeutics ASA (NO) | 2023-03-08 | — | — | EP | disclosed |
| US-20220348613-A1 | ADENO-ASSOCIATED VIRUSES AND METHODS AND MATERIALS FOR MAKING AND USING ADENO-ASSOCIATED VIRUSES | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2022-11-03 | — | — | US | disclosed |
| WO-2021219897-A1 | BETACORONAVIRUS PROPHYLAXIS AND THERAPY | VACCIBODY AS (NO) | 2021-11-04 | — | — | WO | disclosed |
| US-6180084-B1 | CONTACTING PURIFIED NGR RECEPTOR WITH ONE OR MORE MOLECULES AND DETERMINING SPECIFIC BINDING OF MOLECULE TO NGR RECEPTOR, WHERE PRESENCE OF SPECIFIC BINDING IDENTIFIES MOLECULE AS TUMOR HOMING MOLECULE THAT HOMES TO ANGIOGENIC VASCULATURE | THE BURNHAM INSTITUTE | 2001-01-30 | — | — | US | disclosed |
| WO-2000042973-A2 | HOMING PRO-APOPTOTIC CONJUGATES AND METHODS OF USING SAME | THE BURNHAM INSTITUTE (US) | 2000-07-27 | — | — | WO | disclosed |
| EP-1015884-A1 | METHODS OF IDENTIFYING MOLECULES THAT HOME TO ANGIOGENIC VASCULATURE IN TUMORS | The Burnham Institute (US) | 2000-07-05 | — | — | EP | disclosed |
| EP-0927045-A2 | TUMOR HOMING MOLECULES, CONJUGATES DERIVED THEREFROM, AND METHODS OF USING SAME | The Burnham Institute (US) | 1999-07-07 | — | — | EP | disclosed |
| WO-1999013329-A1 | METHODS OF IDENTIFYING MOLECULES THAT HOME TO ANGIOGENIC VASCULATURE IN TUMORS | THE BURNHAM INSTITUTE (US) | 1999-03-18 | — | — | WO | disclosed |
| WO-1998010795-A2 | TUMOR HOMING MOLECULES, CONJUGATES DERIVED THEREFROM, AND METHODS OF USING SAME | THE BURNHAM INSTITUTE (US) | 1998-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050164182-A1 | Nucleoside comprising reporter molecule cleavable by hydrolase such as esterases, phosphatases, peptidases, penicillin amidases, glycosidases, and phosphorylases; limits polymerase activity; sequencing; solid phase synthesis | PNP, PEPD, DNPEP | SLC7A5 2009/4885SLC1A3 2903/4885SLC1A2 3422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.